SERPINB4 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- SERPINB4 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100538
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- SERPINB4 antibody Polyclonal Antibodies Primary antibodies
Related genes to: SERPINB4 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- SERPINB4 NIH gene
- Name:
- serpin family B member 4
- Previous symbol:
- SCCA2
- Synonyms:
- PI11, LEUPIN, SCCA-2, SCCA1
- Chromosome:
- 18q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1995-09-15
- Date modifiied:
- 2016-04-06
Related products to: SERPINB4 antibody Polyclonal Antibodies Primary antibodies
Related articles to: SERPINB4 antibody Polyclonal Antibodies Primary antibodies
- Cervical cancer remains a significant health burden worldwide, particularly in patients with markedly elevated pretreatment serum squamous cell carcinoma antigen levels (≥ 10 ng/mL), who often have poor outcomes. Accurate prognostic tools for this high-risk population are limited. - Source: PubMed
Publication date: 2026/03/07
Zhao YiweiZhao ChutongLiu YujieWang YuanZhang YunyanLiu Sijia - Early detection of oesophageal squamous cell carcinoma (ESCC) is critical for improving survival, yet current screening is hampered by the lack of effective, non-invasive methods. Here, we developed and prospectively validated an extracellular vesicle (EV) protein-based blood test for the preclinical detection of ESCC. We first engineered BarFlare, a high-sensitivity platform for serum EV protein analysis, and identified a novel biomarker panel that includes EV-associated squamous cell carcinoma antigen (SCC) and matrix metalloproteinase-13 (MMP13). These biomarkers were integrated with clinical factors into an interpretable multi-criteria decision-making classification fusion (MCF) machine-learning framework. The MCF model was trained and validated in prospective, multicentre diagnostic cohorts (n = 1018), and its preclinical detection capability was assessed in a prospective, population-based longitudinal cohort. The MCF framework accurately distinguished patients with ESCC from healthy controls in a test set (AUC, 0.987) and two external validation cohorts (AUCs, 0.926 and 0.960), including those with early-stage disease (AUCs, 0.901-0.980). Critically, in the longitudinal cohort, the framework identified individuals who would later develop ESCC from their baseline blood samples with a median lead time of 34.9 months (range, 0.4-72.5) before clinical diagnosis (AUC, 0.864; sensitivity, 73.3%; specificity, 82.2%). The risk score of the model correlated with time to diagnosis, and its dynamic increase significantly outperformed that of traditional serum SCC for preclinical risk stratification. Our validated, blood-based EV protein signature not only accurately detects prevalent ESCC but also identifies high-risk individuals years before clinical presentation, providing a powerful, non-invasive tool that supports risk-stratified screening and creates a critical window for early, potentially curative intervention. Trial Registration: Chinese Clinical Trial Registry identifiers: ChiCTR2200066733 and ChiCTR2200065610. - Source: PubMed
Wang YuXing ShanWu Ya-XianXue NingChen Pei-MinJin Run-XianXu Yi-WeiJi Ming-FangPeng Yu-HuiLiu Yuan-TaoChen Li-NaWu MengJiang Zi-YingXie Shang-HangLuo Yi-LingZhang BiaoOu Xin-YuanHuang QiTian Bo-YuLing LiCao Su-MeiLiu Wan-LiZeng Mu-ShengZhong Qian - This study aimed to evaluate the expression of selected immunohistochemical (IHC) markers and serum squamous cell carcinoma antigen (SCC-Ag) in vulvar squamous cell carcinoma (VSCC), and to investigate associations with recurrence and death using molecular clustering and diagnostic performance analyses. - Source: PubMed
Publication date: 2026/02/12
Della Corte LuigiPalumbo MarioMignogna ChiaraVarricchio SilviaCarbone GianluigiSirica RosaInsabato LuigiTerracciano DanielaBifulco Giuseppe - The objective of this study was to identify key idiopathic pulmonary fibrosis (IPF) related genes, thereby establishing a novel IPF diagnostic/warning panel and proposing drugs against IPF based on the strategy of targeting key genes. - Source: PubMed
Publication date: 2026/01/15
Song YuMeng XianglinTian JiaqiHao YunheZeng KaiZhang LikunZhang JiannanZhang KailiXin YuWang ChangsongYu Kaijiang - In mild atopic dermatitis (AD), evaluating disease activity during maintenance therapy is challenging due to subtle clinical signs. Serum squamous cell carcinoma antigen 2 (SCCA2) has been proposed as a sensitive biomarker, but its utility in assessing disease status specifically in mild AD remains unclear. - Source: PubMed
Yasuda YasuakiIwai FumikoHamada KanaHoshi-Funakawa MiyukiNogami KazutakaMatsunaga MayumiTakase TakafumiNagao MizuhoSuga ShigeruAzuma YoshinoriHirayama MasahiroIzuhara KenjiFujisawa Takao